Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3680
- Registration Number
- NCT06058377
- Locations
- 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery
- First Posted Date
- 2023-09-22
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT06050252
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸UCHealth University of Colorado Hospital, Aurora, Colorado, United States
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06040099
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
- Conditions
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Isala
- Target Recruit Count
- 679
- Registration Number
- NCT06031233
- Locations
- 🇳🇱
Isala Hospital, Zwolle, Netherlands
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
- Conditions
- Interventions
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2024-11-04
- Target Recruit Count
- 27
- Registration Number
- NCT06027086
- Locations
- 🇺🇸
Johns Hopkins SKCCC, Baltimore, Maryland, United States
Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 28
- Registration Number
- NCT06017297
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 280
- Registration Number
- NCT06008093
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
- Conditions
- Interventions
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT05943106
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT05941897
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05935579
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.